Medical Device Manufacturers Must Transition to ISO 13485:2016 and New Risk-Based Submission Frameworks

Executive Summary

On August 3, 2026, the U.S. Food and Drug Administration (FDA) issued a revised version of its final guidance, "Applying Human Factors and Usability Engineering to Medical Devices". This revision marks a critical shift in the regulatory landscape, primarily driven by the implementation of the Quality Management System Regulation (QMSR) and the need for harmonized reporting structures. The update focuses on synchronizing human factors (HF) processes with international standards and optimizing the submission process through a risk-based categorization of documentation.

Guidance Update Highlights

• Alignment with QMSR and ISO 13485:2016: A cornerstone of this update is the formal incorporation of ISO 13485:2016 via the QMSR, which replaced the majority of the previous 21 CFR Part 820 requirements as of February 2, 2026. Manufacturers are now explicitly required to follow internationally recognized regulatory expectations for Quality Management Systems, including how human factors are integrated into design controls.
• Harmonization of Definitions: The 2026 revision updates core definitions—such as "Abnormal Use," "Harm," and "Hazard"—to align with the latest versions of international consensus standards, including IEC 62366-1:2015+AMD1:2020 and ISO 14971:2019. This synchronization ensures that terminology used in HF reports is consistent across global regulatory jurisdictions.
• Restructured Documentation Requirements: Significantly, the FDA has deleted Appendix A, which previously provided a specific HFE/UE report outline. Section 9 on "Documentation" has also been revised to point manufacturers toward the separate final guidance, "Content of Human Factors Information in Medical Device Marketing Submissions," for reporting expectations. This effectively separates the process of conducting HFE/UE from the content required for a marketing submission.

Analysis of Industry Impact

The removal of the legacy report outline in Appendix A means that a "one-size-fits-all" approach to HFE reporting is no longer acceptable. Instead, the FDA now utilizes a risk-based categorization (Category 1, 2, and 3) for submissions, where the depth of required HF information depends on the presence of "critical tasks" and the extent of user interface modifications.

Furthermore, the shift to QMSR requires a top-down review of Design History Files (DHF). Manufacturers who previously relied solely on the 2016 guidance’s internal report structure must now ensure their documentation reflects the latest risk management principles of ISO 14971:2019 and the usability engineering processes of IEC 62366-1.

Recommendations for Organizations

To maintain regulatory compliance and minimize the risk of Refuse-to-Accept (RTA) decisions or additional information requests, organizations should take the following actions:

1. Adopt New Reporting Templates: Immediately stop using the deleted 2016 Appendix A as a template for marketing submissions. Transition to the structure defined in the "Content of Human Factors Information" guidance.
2. Update Risk Management Procedures: Ensure that Use-Related Risk Analysis (URRA) documents utilize the updated definitions and severity scales harmonized with ISO 14971:2019.
3. Audit Quality Management Systems: Verify that internal design control procedures reference QMSR and ISO 13485:2016 standards rather than the superseded 21 CFR 820 clauses.
4. Engage in Pre-Submissions: For innovative or high-risk interfaces, utilize the Q-Submission program to confirm that proposed HF validation protocols meet the latest FDA expectations under the revised framework.

Conclusion

This update represents the FDA’s commitment to modernizing medical device oversight through global harmonization. By integrating HFE/UE more deeply into the total product lifecycle and adopting a risk-proportionate documentation approach, the Agency aims to enhance review efficiency while ensuring that devices are inherently safe for their intended users and environments. Success in this new era requires manufacturers to move beyond mere compliance and treat human factors as a strategic component of product quality and clinical safety.